Prime Medicine, Inc. Earnings Per Share (Basic)
Prime Medicine, Inc. (PRME) reported Earnings Per Share (Basic) of -$0.24 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- Prime Medicine, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.24.
- Prime Medicine, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.28.
- Prime Medicine, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.26.
- Prime Medicine, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.32.
- Prime Medicine, Inc. earnings per share, basic for fiscal 2025 was -$1.35.
- Prime Medicine, Inc. earnings per share, basic for fiscal 2024 was -$1.65.
- Prime Medicine, Inc. earnings per share, basic for fiscal 2023 was -$2.18.
- Prime Medicine, Inc. earnings per share, basic for fiscal 2022 was -$4.19.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.24 10-Q · filed 2026-08-06 | -$0.51 10-Q · filed 2026-08-06 | -$0.77 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.09 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.28 10-Q · filed 2026-05-07 | -$0.54 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$0.85 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.23 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$0.57 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$0.96 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.35 10-K · filed 2026-03-03 |
| 2025-09-30 | -$0.32 10-Q · filed 2025-11-07 | -$0.71 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.11 10-Q · filed 2025-11-07 | -$1.43 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$0.41 10-Q · filed 2026-08-06 | -$0.81 10-Q · filed 2026-08-06 | -$1.13 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.56 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.40 10-Q · filed 2026-05-07 | -$0.72 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.15 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.61 derived: net income ÷ weighted average shares · filed 2026-05-07 |
| 2024-12-31 | -$0.32 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$0.76 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$1.22 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$1.65 10-K · filed 2026-03-03 |
| 2024-09-30 | -$0.44 10-Q · filed 2025-11-07 | -$0.90 derived: net income ÷ weighted average shares · filed 2025-11-07 | -$1.34 10-Q · filed 2025-11-07 | -$2.01 derived: net income ÷ weighted average shares · filed 2025-11-07 |
| 2024-06-30 | -$0.46 10-Q · filed 2025-08-07 | -$0.90 10-Q · filed 2025-08-07 | -$1.58 derived: net income ÷ weighted average shares · filed 2025-08-07 | -$2.13 derived: net income ÷ weighted average shares · filed 2025-08-07 |
| 2024-03-31 | -$0.44 10-Q · filed 2025-05-08 | -$1.13 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$1.68 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$2.16 derived: net income ÷ weighted average shares · filed 2025-05-08 |
| 2023-12-31 | -$0.71 derived: net income ÷ weighted average shares · filed 2025-02-28 | -$1.26 derived: net income ÷ weighted average shares · filed 2025-02-28 | -$1.73 derived: net income ÷ weighted average shares · filed 2025-02-28 | -$2.18 10-K · filed 2025-02-28 |
| 2023-09-30 | -$0.55 10-Q · filed 2024-11-12 | -$1.02 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$1.46 10-Q · filed 2024-11-12 | -$2.01 derived: net income ÷ weighted average shares · filed 2024-11-12 |
| 2023-06-30 | -$0.47 10-Q · filed 2024-08-08 | -$0.91 10-Q · filed 2024-08-08 | -$1.45 derived: net income ÷ weighted average shares · filed 2024-08-08 | -$2.30 derived: net income ÷ weighted average shares · filed 2024-08-08 |
| 2023-03-31 | -$0.44 10-Q · filed 2024-05-10 | -$0.98 derived: net income ÷ weighted average shares · filed 2024-05-10 | -$1.88 derived: net income ÷ weighted average shares · filed 2024-05-10 | -$2.95 derived: net income ÷ weighted average shares · filed 2024-05-10 |
| 2022-12-31 | -$0.55 derived: net income ÷ weighted average shares · filed 2024-03-01 | -$1.59 derived: net income ÷ weighted average shares · filed 2024-03-01 | -$2.89 derived: net income ÷ weighted average shares · filed 2024-03-01 | -$4.19 10-K · filed 2024-03-01 |
| 2022-09-30 | -$1.61 10-Q · filed 2023-11-03 | -$3.36 derived: net income ÷ weighted average shares · filed 2023-11-03 | -$4.91 10-Q · filed 2023-11-03 | -$8.75 derived: net income ÷ weighted average shares · filed 2023-11-03 |
| 2022-06-30 | -$1.76 10-Q · filed 2023-08-07 | -$3.31 10-Q · filed 2023-08-07 | -$7.26 derived: net income ÷ weighted average shares · filed 2023-08-07 | -$8.92 derived: net income ÷ weighted average shares · filed 2023-08-07 |
| 2022-03-31 | -$1.58 10-Q · filed 2023-05-11 | -$5.59 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$7.25 derived: net income ÷ weighted average shares · filed 2023-05-11 | |
| 2021-12-31 | -$4.20 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$5.85 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$14.19 10-K · filed 2023-03-09 | |
| 2021-09-30 | -$1.52 10-Q · filed 2022-11-14 | -$9.74 10-Q · filed 2022-11-14 | ||
| 2020-12-31 | -$1.91 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |